Item 8.01. Other Events
On June 16, 2008, ACADIA Pharmaceuticals Inc. issued a press release announcing top-line results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. ACADIA does not anticipate conducting further studies with ACP-104, but will continue to advance its broad pipeline of drug candidates, including its lead program with pimavanserin for the treatment of Parkinson's disease psychosis, which is currently in Phase III trials.
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
ACADIA Pharmaceuticals Inc.
|
||||||
|
Date: June 16, 2008
|
By:
|
/s/ Glenn F. Baity
|
||||||
|
Glenn F. Baity
|
||||||||
|
Vice President & General Counsel
|
||||||||